Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KamadaXTAE:KMDA -0.28%84 Days Payable is 78.91 as of Mar. 2026, which is 22% below its 10-year median of 100.92. GuruFocus rates XTAE:KMDA with a GF Score™ of 84/100 and a GF Value™ of ₪25.14 (Modestly Undervalued). Among 927 Drug Manufacturers companies, Kamada ranks worse than 54.8% on this metric.
Kamada's average Accounts Payable for the
three
months ended in Mar. 2026 was ₪67.9 Mil. Kamada's Cost of Goods Sold for the
three
months ended in Mar. 2026 was ₪78.5 Mil.
Hence, Kamada's Days Payable for the
three
months ended in Mar. 2026 was 78.91.
The historical rank and industry rank for Kamada's Days Payable or its related term are showing as below:
XTAE:KMDA'
s Days Payable Range Over the Past 10 Years
Min: 81.93 Med: 100.92 Max: 128.14
Current: 81.93
During the past 13 years, Kamada's highest Days Payable was 128.14. The lowest was 81.93. And the median was 100.92.
XTAE:KMDA's Days Payable is ranked worse than 54.8% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.16
vs XTAE:KMDA: 81.93
Kamada's Days Payable
declined
from Mar. 2025 (103.11) to Mar. 2026 (78.91).
It may suggest that Kamadaaccelerated paying its suppliers.
The historical data trend for Kamada's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:KMDA vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kamada Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kamada's Days Payable distribution charts can be found below:
* The bar in red indicates where Kamada's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Kamada's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kamada (XTAE:KMDA) has a Days Payable of 78.91 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Kamada and its competitors. This is 22% below median its historical median of 100.92. Over the past decade, Kamada's Days Payable has ranged from 81.93 to 128.14. According to the industry distribution chart, Kamada ranks #508 out of 927 companies in the Drug Manufacturers industry, placing it in the top 54.8%.
Is Kamada's Days Payable too high?
Kamada's current Days Payable of 78.91 is 22% below median its 10-year median of 100.92. Over the past 10 years, this metric has ranged from a low of 81.93 to a high of 128.14. The Drug Manufacturers industry median Days Payable is 90.16. Kamada's value of 78.91 is 12.5% below this industry median. Based on the distribution chart, Kamada ranks #508 out of 927 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Kamada has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kamada's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kamada ranks #508 out of 927 companies for Days Payable. This places Kamada in the lower half of its industry. The industry median Days Payable is 90.16. Kamada's value of 78.91 is 12.5% below this benchmark. Historically, Kamada's own Days Payable has ranged from 81.93 to 128.14 over the past decade. While the company's 10-year median is 100.92 vs. the industry median of 90.16, Kamada has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.16, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kamada's current Days Payable of 78.91 is 12.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Kamada and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kamada's current Days Payable is 78.91, which is 22% below median its own 10-year median of 100.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kamada stock overvalued right now?
Based on GuruFocus' analysis, Kamada (XTAE:KMDA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₪25.14, compared to a current price of ₪21.74 — trading 13.5% below its estimated fair value. The current Days Payable is 78.91, which is 22% below median its 10-year median of 100.92 and 12.5% below the Drug Manufacturers industry median of 90.16. Kamada's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Kamada (XTAE:KMDA), the current Days Payable is 78.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kamada (XTAE:KMDA) Overvalued in 2026?
Based on GuruFocus' analysis, Kamada stock appears to be undervalued.
The current stock price of ₪21.74 is trading 13.5% below its estimated GF Value™ of ₪25.14.
GuruFocus considers Kamada to be Modestly Undervalued.
Key valuation signals for XTAE:KMDA:
Days Payable: 78.91 (22% below median its 10-year median of 100.92)
GF Value™: ₪25.14 vs. price of ₪21.74 (13.5% below fair value)
Industry Position: 12.5% below the Drug Manufacturers median (#508 of 927)
No single metric tells the full story. See the XTAE:KMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
84GF Score
Get the complete analysis for XTAE:KMDA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:KMDA has been successfully added to your 
